Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy receives additional FDA approval

Gives the nod for Yervoy as adjuvant treatment option for melanoma

- PMLiVE

Roche appoints new UK general manager

Richard Erwin was previously the company's general manager for Belgium

Roche Basel Switzerland

Roche’s Kadcyla fails in gastric cancer trial

Results are a major blow to the firm's ambition of expanding the indications for its breast cancer drug

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Bristol-Myers Squibb (BMS) building

BMS signs $1.74bn deal to boost immuno-oncology portfolio

Gainsaccess to Five Prime Therapeutics CSF1R antibody programme

- PMLiVE

BMS promotes Paul Biondi to head of business development

He willnow lead the development of its strategic partnerships

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

BMS recruits Jack Huston for European Lung cancer campaign

TheBoardwalk Empire actor will work with the firm on an awareness drive

- PMLiVE

Indian court blocks generic of Merck’s Januvia

Follows a series of setbacks in Indian courts for multinational pharma companies

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

- PMLiVE

Roche faces Kadcyla pricing pressure in the UK

Leading breast cancer charity calls on firmto reduce the drug's cost

Roche Basel Switzerland

Roche’s investigational drug first to show efficacy in MS

Ocrelizumab shows positive results in large phase III study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links